ArticleInfection2016
Gaseous nitric oxide to treat antibiotic resistant bacterial and fungal lung infections in patients with cystic fibrosis: a phase I clinical study.
Article in Infection, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 2 registered trials, which are not on this map. Cited by 50 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
An Open Label Safety Study of Inhaled Gaseous Nitric Oxide (gNO) for Adults & Adolescents With Non-Tuberculous Mycobacteria, Burkholderia Spp, Aspergillus Spp and Corona-like Viral (Sub-Study) Infections
Multi-Center, Randomized, Controlled, Phase II Clinical Efficacy Study Evaluating Nitric Oxide Releasing Solution Treatment for the Prevention and Treatment of COVID-19 in Healthcare Workers and Individuals at Risk of Infection
Who cites it
50 citing papers in PubMed, 110 citations in OpenAlex.
- High-Dose Inhaled Nitric Oxide in Acute Hypoxemic Respiratory Failure Due to COVID-19: A Multicenter Phase II Trial.American journal of respiratory and critical care medicine · 2023Trial
- Safety and practicality of high dose inhaled nitric oxide in emergency department COVID-19 patients.The American journal of emergency medicine · 2022Trial
- High-dose inhaled nitric oxide for severe pneumonia caused by multidrug-resistant bacteria: a randomized controlled trial protocol.Annals of medicine · 2026Article
- The therapeutic potential of high-dose inhaled nitric oxide for antimicrobial effects: a narrative review and future directions.Intensive care medicine experimental · 2026Review
- Antimicrobial Resistance: The Answers.British journal of biomedical science · 2026Review
- Penetration and Preliminary Efficacy of a Novel Nitric Oxide-Releasing Gel for Onychomycosis.Journal of fungi (Basel, Switzerland) · 2025Article
- Gasotransmitters in Modern Medicine: Promises and Challenges in the Use of Porous Crystalline Carriers.Advanced healthcare materials · 2025Review
- Efficacy of nitric oxide donors and EDTA againstBiofilm · 2025Article
- Insights on the Pathogenesis ofJournal of clinical medicine · 2025Review
- Nitric Oxide in the Treatment of COVID-19: Nasal Sprays, Inhalants and Nanoparticles.Biochemistry research international · 2025Review
- Biomedical Metal-Organic Framework Materials: Perspectives and Challenges.Advanced functional materials · 2024Article
- Article
- Nanotechnology-Based Drug Delivery Systems to Control Bacterial-Biofilm-Associated Lung Infections.Pharmaceutics · 2023Review
- Biomimetic catheter surface with dual action NO-releasing and generating properties for enhanced antimicrobial efficacy.Journal of biomedical materials research. Part A · 2023Article
- Drug delivery strategies for antibiofilm therapy.Nature reviews. Microbiology · 2023Review
- The Triple Crown: NO, CO, and HPharmacology & therapeutics · 2023Review
- Development of nitric oxide generators to produce high-dose nitric oxide for inhalation therapy.Nitric oxide : biology and chemistry · 2023Article
- Gaseous nitric oxide failed to inhibit the replication cycle of SARS-CoV-2 in vitro.Nitric oxide : biology and chemistry · 2023Article
- Review
- Inhaled nitric oxide: can it serve as a savior for COVID-19 and related respiratory and cardiovascular diseases?Frontiers in microbiology · 2023Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 5 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundIndividuals with cystic fibrosis (CF) receive antibiotics continuously throughout their entire life which leads to drug resistant microbial lung infections which are difficult to treat. Nitric oxide (NO) gas possesses antimicrobial activity against a wide variety of microorganisms in vitro, in vivo in animal models and a phase I study in healthy adults showed administration of intermittent 160 ppm NO to be safe.
methodsWe assessed feasibility and safety of inhaled NO in eight CF patients who received 160 ppm NO for 30 min, three times daily for 2 periods of 5 days.
resultsThe NO treatment was safe and in none of the patients were serious drug-related adverse events observed which caused termination of the study. The intention-to-treat analysis revealed a significant mean reduction of the colony forming units of all bacteria and all fungi, while mean forced expiratory volume 1 s % predicted (FEV1) relative to baseline increased 17.3 ± 8.9 % (P = 0.012).
conclusionsNO treatment may improve the therapy of chronic microbial lung infections in CF patients, particularly concerning pathogens with intrinsic or acquired resistance to antibiotics.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.